{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["79(6)"],"submitter":["Brooks JT"],"funding":["BENEFIT Kids"],"pubmed_abstract":["<h4>Background</h4>Linezolid, a component of rifampicin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB) treatment, is associated with treatment-limiting toxicities, including anemia. Patient-level and linezolid pharmacokinetic risk factors for anemia have not been well described in children treated for RR/MDR-TB.<h4>Methods</h4>We evaluated the pharmacokinetics of linezolid and longitudinal hemoglobin data to validate an existing population linezolid pharmacokinetic model. We assessed the impact of linezolid pharmacokinetics and the risk of developing anemia in a prospectively enrolled cohort of children. A previously published population pharmacokinetic linezolid model was validated using nonlinear mixed effects modeling. A multivariable ordinal logistic regression model was built "],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pagination":["1495-1502"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11650862"],"repository":["biostudies-literature"],"pubmed_title":["Linezolid Pharmacokinetic-Anemia Modeling in Children With Rifampicin-Resistant Tuberculosis."],"pmcid":["PMC11650862"],"pubmed_authors":["Furin J","Brooks JT","Draper HR","Solans BP","van der Laan L","Sharma S","Schaaf HS","Savic RM","Beranger A","Hesseling AC","Garcia-Prats AJ"],"additional_accession":[]},"is_claimable":false,"name":"Linezolid Pharmacokinetic-Anemia Modeling in Children With Rifampicin-Resistant Tuberculosis.","description":"<h4>Background</h4>Linezolid, a component of rifampicin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB) treatment, is associated with treatment-limiting toxicities, including anemia. Patient-level and linezolid pharmacokinetic risk factors for anemia have not been well described in children treated for RR/MDR-TB.<h4>Methods</h4>We evaluated the pharmacokinetics of linezolid and longitudinal hemoglobin data to validate an existing population linezolid pharmacokinetic model. We assessed the impact of linezolid pharmacokinetics and the risk of developing anemia in a prospectively enrolled cohort of children. A previously published population pharmacokinetic linezolid model was validated using nonlinear mixed effects modeling. A multivariable ordinal logistic regression model was built ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-22T10:44:02.575Z","creation":"2025-04-05T23:41:25.007Z"},"accession":"S-EPMC11650862","cross_references":{"pubmed":["39422476"],"doi":["10.1093/cid/ciae497"]}}